Kuvan®'s Effect on the Cognition of Children With Phenylketonuria
Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The study is a single-cohort, interventional, open-label trial to evaluate long-term
neurocognitive (NC) outcomes in children aged 4 to 5 years with phenylketonuria (PKU) treated
with Kuvan® and Phenylalanine-restricted diet over a period of 7 years.